11 August 2021>: Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 4 Adverse events of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
Event, n (%) | ITT (n=36) | |
---|---|---|
Any grade | Grade 3 or 4 | |
Neutropenia | 17 (47.2) | 6 (16.7) |
Anemia | 9 (25.0) | 0 |
Leukopenia | 9 (25.0) | 0 |
Thrombocytopenia | 3 (8.3) | 0 |
Increased ALT | 2 (5.6) | 1 (2.8) |
Increased bilirubin | 1 (2.8) | 1 (2.8) |
ALT – alanine transaminase; ITT – intention-to-treat. |